Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2012

- 1. Overview of consolidated results
- 2. Actual and Forecast of Main Subsidiary Companies
- 3. Main Product Sales Update
- 4. Development pipeline

[Reference]

- 5. Segment information
- 6. Financial summary

February 3, 2012 KYORIN Holdings, Inc.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.



Outline of Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2012



YoY YoY Mar/2012 (¥ million) Dec/2008 Dec/2009 Dec/2010 Dec/2011 change change (forecast) (%) (%) **Net Sales** 66,361 74,579 75,821 77,413 +2.1% 105,100 +1.0% 14,900 5,339 11,045 11,312 11,668 **Operating Income** +3.1% **△9.4% Ordinary Income** 5,451 11,860 11,848 12,358 +4.3% 15,600 △8.8% 7,535 842 7,537 7,227 **∆4.1%** 10,100 **∆7.6%** Net Income

Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2012

[Net sales] Sales of Japan ethical drugs increased for steady sales of our main products year on year ,under the influence of the excess distribution inventory at the end of the fiscal year ended March in association with the Great East Japan Earthquake. Sales of overseas ethical drugs this year was less than that of last year, and sales of generic drugs had no fluctuation as compared to last year. As a result, Consolidated Net Sales increased 2.1% year on year, to ¥77.4 billion.

[Net income] Gross Profit rose due to the increase of Net Sales and decrease of Cost of Sales . SG&A Expenses rose due to increase of R&D Expenses for progress of R&D. Net Income decreased 4.1%, to ¥7.2 billion year on year, due to the tax system revision and amortized deferred tax asset.

Consolidated Financial Results for the Fiscal Year Ending March 31, 2012(forecast)


[Net sales, Net income] We will not revise the full-year (consolidated) results forecast of Net sales and Net income announced on November 8, 2011 at this moment.

(degree of progress: Net sales: 73.7%, operating income: 78.3%)

Highlights of Business Performance



(Units: ¥ billion)



Consolidated Financial Results for the Third Quarter ending March 31, 2012

≪Dec/2010(actual) vs.Dec/2011(actual)≫

(¥ billion)	Dec/2010	Dec/2011	change
Net Sales (total)	75.8	77.4	+1.6
Ethical drugs Business	73.8	75.5	+1.7
Sales of new ethical drugs	64.0	66.0	+2.0
●Japan	62.2	64.6	+2.4
●Overseas	1.8	1.4	△0.4
♦Generic drugs	6.5	6.5	0.0
Over-the- counter drugs	3.2	3.0	△0.2
Healthcare (Skin care) Business	2.1	1.9	△0.2
Operating Income	11.3	11.7	+0.4
Ordinary Income	11.8	12.4	+0.6
Net Income	7.5	7.2	∆0.3

			iou oniou
■Net Sales		¥77.4bln	(+ 1.6)
Ethical drugs	business	¥75.5bln	(+ 1.7)
	w ethical drugs ec/2010 ⇒Dec/2011	¥64.6bln	(+ 0.2)
 Kipres Mucodyne Pentasa Uritos 	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$		
Sales of new et	hical drugs in Overseas	¥1.4bln	(△0.4)
 Gatifloxacin 	$1.5 \Rightarrow 1.2 (\triangle 0.5)$)	
	ic drugs ice pharmacy market's sale facturing's sales decreasec		(0.0)
-	he-counter drugs	¥3.0bln	(△0.2)
♦Healthcare (Sk	in care) Business	¥1.9bln	(△0.2)
Sales declined a	it Dr. Program		(△0.2)
■Operating Inc	ome	¥11.7bln	(+ 0.4)
♦ Operating Inc	ome margin rose 0.2	percentage poir	<u>nts to 15.1%</u>
 Cost of Sal Increased a rise in th R&D expense R&D Ratio Expenses a (Application) 	s : down ¥0.3bln (¥27. es Ratio : 36.5%⇒35.4% sales of in-house products e factory operation ratio , ies : up ¥1.1bln (¥9.1b : 12.0%⇒13.2% up 1.2 p associated with the progress of Pentasa ,Once a day oral uding R&D expenses)	down 1.1 percentages with lower cost of satisfies a decrease of manufacture of the R&D administration etc.)	les facturing cost
♦SG&A Rati	o (excluding R&D expenses)	: 36.5%⇒36.3% dowr	0.2 percentage points
■Net Income	, , , , , , , , ,	¥7.2bln	(∆0.3)
 Amortized d 	eferred tax asset due to the	tax system revision.	3



Year on Year

Actual and Forecast of Main Subsidiary Companies Kyorin

(unit : billion)

Mar/2012

(forecast)

94.7

14.2

9.9

KYORIN pharmaceutical	Dec/2010	Dec/2011
Sales	67.2	70.3
Operating Income	10.6	11.2
Net Income	7.2	7.2

Mar/2011	Mar/2012 (forecast)
10.3	10.5
0.8	0.6
0.6	0.5

Mar/2011

92.5

15.6

10.7

KYORIN Rimedio	Dec/2010 **	Dec/2011
Sales	7.7	7.1
Operating Income	0.5	0.3
Net Income	0.5	0.3

Dr. Program	Dec/2010	Dec/2011
Sales	2.1	1.9
Operating Income	0.1	0.0
Net Income	0.1	0.0

Mar/2011	Mar/2012 (forecast)
2.8	2.8
0.1	0.1
0.1	0.1

*Associated with the integration of the wholesale trade channel into KYORIN Pharmaceutical ((October 1), beginning inventories are posted in sales(¥0.6bln).



(Units: ¥ billion)

		Interin	n term	Third quarter (April 1 to December 31,2010)				Full term	
		FY10 (results)	FY11 (results)	FY10 (results)	FY11 (results)	Change	Progress to full term forecast(%)	FY10 (results)	FY11 (forecast)
	Kipres (LT receptor antagonist)	14.1	15.7	24.4	27.6	13.2%	75.3%	34.5	36.7
Sales of new	Mucodyne (Mucoregulant)	9.4	9.1	15.9	16.0	0.8%	75.0%	21.3	21.3
ethical drugs (Japan)	Pentasa (Ulcerative colitis and Crohn's disease treatment)	9.9	9.1	15.1	14.2	△6.3%	76.1%	19.4	18.6
	Uritos (Kyorin) (Overactive bladder)	2.4	2.9	3.9	4.8	21.9%	71.9%	5.5	6.6
	Ketas (For bronchial asthma and cerebrovasculas disorders)	2.0	1.8	3.0	2.7	∆9.9%	76.3%	4.0	3.5
Sales of new ethical drugs (over seas)	Gatifloxacin (Bulk · Royalty)	1.3	0.8	1.5	1.2	∆21.6%	70.2%	2.2	1.7
Consumer Healthcare business	Milton (Disinfectant)	0.9	0.9	1.5	1.5	1.4%	75.4%	1.9	2.0

Main R&D Activities (February 3, 2012 Release)



Ph IIb Application submitted

*Changes from the previous announcement (November 8, 2011)

	Stage	Compound/	Therapy	Origin	Features	Comments	
Japan	Overseas	Code	area/Action	Origin	reatures	Comments	
*Application submitted (11/2011)		Pentasa (tablet)	Ulcerative colitis	Ferring Pharmaceuticals	New dosage regimen for ulcerative colitis in the remission phase (once a day)		
PhⅢ (11/2010)		Pentasa (suppository)	Ulcerative colitis	Ferring Pharmaceuticals	Consideration of a new dosage form for the active phase of ulcerative colitis (once a day)	*Development of a new dosage form	
PhⅢ (8/2010)	(US) SkyePharma : Application submitted (3/2009) (Europe) Mundipharma : Application submitted (3/2010)	KRP-108 (Inhalant)	Anti- asthmatic	SkyePharma PLC	An ICS/LABA combination product, which offers better compliance and convenience to the patients	 License agreement with SkyePharma (4/2008) Domestic Ph II completed (4/2010) 	
Ph II (2/2008)	Ph II (9/2007)	KRP-104	Anti-diabetes agent	In-house	A DPPIV inhibitor to reduce blood glucose through suppression of the degradation of insulin-releasing hormone. Diabetic therapy with fewer side effects is expected than existing treatments.	 Overseas Ph II b completed (3/2011) Domestic Ph II b completed (3/2010) 	

Main R&D Activities 2 (February 3, 2012 Release)



POC Project (Pre-clinical ~ Ph II)			Changes from the previous (November 8, 2011)	s announcement			
		Compound/ Code	Therapy area/Action	Origin	Features	Comments	
Japan Ph I (12/2010)	Overseas Ph II (POC) (12/2010) (Novartis)	KRP-203	Transplantation, autoimmune diseases,and IBD	In-house	An immunosuppressant with a novel mechanism called an S1P-agonist. It may have a better safety profile than previous ones as well as an excellent effect under concomitant use with other types of immunomodulator.	License agreement with Novartis (2/2006) New license agreement IBD (11/2010)	
	Ph I (8/2010)	KRP-110	Opioid-induced constipation and intractable pruritus	In-house	A highly selective µ-opioid receptor antagonist. It is expected to block constipation induced by opioid analgesics without interrupting the analgesic effect of opioids. It is orally effective in various itching models, indicating potential of a novel anti-itch drug for intractable pruritus.		
Ph II *(8/2011)	PhIII Merz	KRP-209	Tinnitus	Merz	KRP-209 (Neramexane) is expected to improve the patients' annoyance and difficulties in their life caused by tinnitus, mainly through its two pharmacological properties: 1) NMDA antagonistic activity and 2) Nicotinic acetylcholine antagonistic activity	License agreement with Merz (11/2009) Merz:Ph I clinical trial of Japanese patients in US completed (3/2010)	
Preparing for clinical trials	(Europe) Almirall : Preparing for application (US) Forest Pharmaceuticals : Preparing for application	KRP-AB1102 (Inhaled drug)	Chronic Obstructive Pulmonary Disease (COPD)	Almirall	This bronchodilating agent has an acetylcholine receptor antagonist action that offers long-lasting improvement for breathing difficulty and shortness of breath associated with COPD. ①Fewer sistemic side effects ②Twice-daily dosage offers a full-day improvement in symptoms and respiratory function ③Short time required for the maximum effectLicense agre Almirall (2/2)		
Ph I *(8/2011)		KRP-AM1977X (Oral agent)	New quinolone synthetic antibacterial agent	In-house	 ①Superior ability to combat drug-resistant gram- positive bacteria (incl. MRSA) ②Outstanding ADME (oral absorption, tissue 		
Ph I preparations		KRP-AM1977Y (Injection)	New quinolone synthetic antibacterial agent	In-house	migration) ③High degree of safety expected since safety hurdles cleared prior to clinical trials		

Main R&D Activities ③ (February 3, 2012 Release)



Licensing Development

*Changes from the previous announcement (November 8, 2011)

Stage	Compound/Code	Licensee/Collaborative research	Therapy area/Action	Origin	Comments
**Approval (1/2012)	Alphagan /AlphaganP	Senju Pharmaceuticals	Glaucoma	Allergan (US)	 Licensed from Allergan (Cross license of gatifloxacin ophthalmic solution) License-out to Senju (5/2004)
Overseas Ph II (8/2005)	Ketas	MediciNova (US)	Cerebrovascular disorders	In-house	•KYORIN grants MediciNova an exclusive license in all countries worldwide except for Japan, China, South Korea and Taiwan to develop, manufacture and sell the compound and products for the multiple sclerosis indication (10/2004) Result of Ph II was reported in April 2008
Overseas Ph III (Anti-bronchial Asthma: 11/2006) Overseas Ph II / III (Interstitial cystitis: 5/2005)	KCA-757	MediciNova (US)	Bronchial asthma and interstitial cystitis	In-house	 •KYORIN grants MediciNova an exclusive license in all countries worldwide except for Japan, China, South Korea and Taiwan to develop and sell the compound and products •Interstitial cystitis: Result of Ph II/III was reported in January 2007 and development ceased •Bronchial asthma: Clinical trial overseas was discontinued.
Overseas Ph II (POC) (12/2010)	KRP-203	Novartis (Switzerland)	Transplantation, autoimmune, and IBD	In-house	 Kyorin grants the right to develop and commercialize KRP-203 worldwide for use as an immunosuppressant in organ transplants, and right to develop and commercialize KRP-203 worldwide except in Japan, Korea, China and Taiwan for the treatment of autoimmune diseases and other diseases (February 2006)) New license agreement IBD (November 2010)



Reference



Sales, Profit or Loss of each report segment

(Units:¥ billion)	Sales	Year on Year	Profit	Year on Year
Net Sales (total)	77.4	+1.6	11.7	+0.4
Ethical drugs business	75.5	+1.7	11.5	+0.5
Sales of new ethical drugs	66.0	+2.0		
●Japan	64.6	+2.4		
Overseas	1.4	△0.4		
♦Generic drugs	6.5	△0.0		
Over-the-counter drugs	3.0	△0.2		
Healthcare(Skincare) business	1.9	△0.2	0.0	△0.0
Amount of adjustment	_	—	0.2	+0.0

(Note) The Company is applying the Revised Accounting Standard for Disclosures about Segments of an Enterprise and Related Information and the Guidance on the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information. As a result, the reported segments are the Ethical Drugs Business and the Consumer Healthcare Business.

Consolidated Financial Results for the Third Quarter ending March 31, 2012



(Units: ¥ million)	Interim term		Third quarter (April 1,2011 to December 31,2011)					Full term	
	FY10 (results)	FY11 (results)	FY10 (results)	FY11 (results)	YoY change	YoY Change(%)	Progress to full term forecast(%)	FY10 (results)	FY11 (forecast)
Sales	46,707	46,387	75,821	77,413	1,592	2.1%	73.7%	104,069	105,100
Ethical drugs business	45,373	45,155	73,751	75,495	1,744	2.4%	73.9%	101,271	102,200
Sales of new ethical drugs	39,208	39,098	64,033	65,996	1,963	3.1%	74.7%	88,020	88,300
●Japan	37,708	38,129	62,188	64,562	2,373	3.8%	74.9%	85,284	86,200
●Overseas	1,500	968	1,844	1,434	∆410	△22.3%	68.3%	2,736	2,100
♦ Generic drugs	4,115	4,097	6,498	6,450	∆48	△0.7%	66.5%	8,871	9,700
♦OTC drugs and others	2,049	1,959	3,218	3,047	△170	△5.3%	72.5%	4,378	4,200
Consumer healthcare business	1,333	1,232	2,070	1,918	△151	∆7.3%	68.5%	2,797	2,800
Operating income	4,201	4,900	11,312	11,668	355	3.1%	78.3%	16,443	14,900
Ordinary income	4,542	5,253	11,848	12,358	509	4.3%	79.2%	17,110	15,600
Net income	2,959	3,355	7,535	7,227	∆308	∆4.1%	71.6%	10,927	10,100